✨ Onyx Summary Saama launched its Tables, Listings, and Figures (TLF) Analyzer, an AI-driven solution that automates interpretation and summarization of complex clinical data to accelerate clinical study report (CSR) authoring. Integrating multimodal GenAI capable of converting graphical outputs—such as Kaplan–Meier and forest plots—into context-rich text, the tool
✨ Onyx Summary Foghorn Therapeutics (Nasdaq: FHTX) announced advancements across its targeted protein degrader portfolio, including progress on its selective ARID1B, CBP, and EP300 degrader programs, with preclinical data showing promise in multiple solid and hematologic cancers and an IND filing for its CBP degrader planned for 2026. The updates underscore
✨ Onyx Summary Seer, Inc. (Nasdaq: SEER) announced its participation in upcoming investor events, including one-on-one meetings at the UBS Global Healthcare Conference on November 12 and a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20. Live and archived webcasts of the
✨ Onyx Summary Kyverna Therapeutics (Nasdaq: KYTX) announced positive interim results from the Phase 2 portion of its registrational KYSA-6 trial showing that a single dose of KYV-101, a CD19 CAR T-cell therapy, achieved rapid, durable, and clinically meaningful improvements in all treated patients with generalized myasthenia gravis. The therapy demonstrated
✨ Onyx Summary Belite Bio (Nasdaq: BLTE) announced that its executive management team will present a corporate update at the Deutsche Bank ADR Virtual Investor Conference on November 4, 2025, at 10:30 a.m. ET. SAN DIEGO, Oct. 29, 2025 – Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a
✨ Onyx Summary Legend Biotech (NASDAQ: LEGN) announced it will host a conference call on November 12, 2025, at 8:00 a.m. ET to discuss its third-quarter financial results and business performance. The company, co-developer of CARVYKTI® for multiple myeloma, continues to expand its leadership in cell therapy and build
✨ Onyx Summary Recursion (Nasdaq: RXRX) announced it will report third-quarter 2025 financial results and provide business updates on November 5, 2025, before market open, followed by a live-streamed “(L)earnings Call” at 8:00 a.m. ET across its social media channels. The company continues to leverage its Recursion OS
✨ Onyx Summary Verily announced a collaboration with NVIDIA to integrate NVIDIA’s AI technology stack—including NeMo, Parabricks, and CUDA-X—into its Pre platform, significantly accelerating genomic and AI model analyses across healthcare research environments such as the NIH’s All of Us Researcher Workbench. The partnership enhances Verily’s
✨ Onyx Summary Geron Corporation (Nasdaq: GERN) announced it will release its third-quarter 2025 financial results and business highlights before market open on November 5, 2025, followed by a conference call and webcast at 8:00 a.m. ET. The live and archived webcast will be accessible on Geron’s investor
✨ Onyx Summary Guardant Health (Nasdaq: GH) and Zephyr AI announced a strategic partnership to combine Guardant’s multimodal molecular data with Zephyr’s AI and machine learning technologies to advance cancer biomarker discovery, drug development, and treatment response prediction. The collaboration, part of Guardant’s Infinity AI platform, underscores a
✨ Onyx Summary Avidity Biosciences (Nasdaq: RNA) entered into a definitive agreement to be acquired by Novartis AG for $72.00 per share in cash, valuing Avidity at approximately $12 billion, following the planned spin-off of its early-stage precision cardiology programs into a new public company, SpinCo. The transaction, unanimously approved
✨ Onyx Summary Guardant Health (Nasdaq: GH) announced new data to be presented at the 2025 American College of Gastroenterology Annual Meeting demonstrating that its FDA-approved Shield blood test achieved over 90% adherence for colorectal cancer screening, significantly higher than traditional methods. The company also shared survey findings showing patient preference
✨ Onyx Summary Kyverna Therapeutics (Nasdaq: KYTX) reported positive Phase 1 results from an investigator-initiated trial of KYV-101, its CD19 CAR T-cell therapy, in treatment-refractory rheumatoid arthritis, showing strong CAR T-cell expansion, full B-cell depletion, and meaningful clinical responses with no high-grade adverse events. Presented by Charité – University of Berlin at
✨ Onyx Summary Phathom Pharmaceuticals (Nasdaq: PHAT) announced the publication of additional analyses from its Phase 3 pHalcon-NERD-301 trial in The American Journal of Gastroenterology, demonstrating that VOQUEZNA® (vonoprazan) significantly improved nighttime reflux symptoms in patients with Non-Erosive Reflux Disease (NERD). The results highlight VOQUEZNA’s sustained nocturnal symptom relief and
✨ Onyx Summary Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire Adverum Biotechnologies (Nasdaq: ADVM) and its lead gene therapy candidate, Ixo-vec, for up to $12.47 per share, including $3.56 in cash and a contingent value right worth up to $8.91 based on future
✨ Onyx Summary Perspective Therapeutics (NYSE American: CATX) announced it will report third-quarter 2025 financial results and provide a business update on November 10, 2025, after market close. The company continues advancing its 212Pb-based theranostic platform with active Phase 1/2a trials in neuroendocrine tumors, melanoma, and solid tumors, supported by
